Jci_page_head_homepage_01 Jci_page_head_homepage_02
William J. Zinnanti, Jelena Lazovic, Cathy Housman, Kathryn LaNoue, James P. O’Callaghan, Ian Simpson, Michael Woontner, Stephen I. Goodman, James R. Connor, Russell E. Jacobs, Keith C. Cheng
Published in Volume 117, Issue 11
J Clin Invest. 2007; 117(11):3258–3270 doi:10.1172/JCI31617
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 10
Proposed mechanism of susceptibility and effect of treatment.

Increased lysine accumulation associated with the catabolic state of fasting illness or lysine loading results in accumulation of glutaric acid in the context of GCDH deficiency. Increased glutarate accumulation in the brain and liver leads to Krebs cycle inhibition as proposed in Figure 6. In the liver, Krebs cycle inhibition leads to inhibition of gluconeogenesis resulting in hypoglycemia. Hypoglycemia stimulates the use of alternate energy substrates in the brain including ketone bodies and ketogenic amino acids. Increased brain lysine utilization leads to enhanced glutarate accumulation and Krebs cycle inhibition. Krebs cycle inhibition in the brain results in depletion of glutamate, GABA, and ATP, with subsequent neuronal injury. Homoarginine blocks brain lysine uptake and controls glutarate accumulation from the substrate level. Glucose supplementation prevents hypoglycemia and the demand for ketone bodies and ketogenic amino acids.